Medigene AG (0QGJ.L) LSE

0.09

-0.095(-51.35%)

Updated at April 29 06:36PM

Currency In EUR

Medigene AG

Address

Lochhamer Strasse 11

Munich, 82152

Germany

Phone

49 89 2000 330

Sector

Healthcare

Industry

Biotechnology

Employees

87

First IPO Date

December 07, 2007

Key Executives

NameTitlePayYear Born
Dr. Selwyn Ho MB BS, MBBSChief Executive Officer & Chairman of Executive Management Board429,0001971
Dr. Ernst-Ludwig WinnackerCo-Founder & Chairman Scientific Advisory Board20,0001941
Dr. Dolores J. Schendel Ph.D.Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development470,000N/A
Dr. Kirsty Crame M.D.Vice President and Head of Clinical Research & Development0N/A
Pamela KeckVice President of Investor Relations & Corporate Communications0N/A
Dr. Birger KohlertChief Financial Officer0N/A

Description

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.